Table 3.
Adherence to Chelation in Adolescents/Adults.
| Chelation Adherence | ||
|---|---|---|
|
| ||
| Chelator | Na | % Adherenceb |
| Monotherapy | ||
| DFO (infusion) | 171 | 91.8 |
| Deferasirox (oral) | 494 | 96.2 |
| Deferiprone (oral) | 23 | 95.5 |
|
| ||
| DFO/Deferasirox combination therapy | ||
| DFO (infusion) | 49 | 91.2 |
| Deferasirox (oral) | 49 | 90.1 |
|
| ||
| DFO/Deferiprone combination therapy | ||
| DFO (infusion) | 80 | 87.8 |
| Deferiprone (oral) | 90 | 95.5 |
a
Sample size includes multiple observations per person over time. The same individual could be counted for different chelators if they changed chelators during the study.
b
Adherence to oral deferasirox was significantly higher than to DFO infusion (p<0.001, repeated measures ANOVA). Adherence to oral deferasirox on DFO/deferasirox combination therapy was lower than that of monotherapy (p<0.001). Adherence to DFO infusion on DFO/deferiprone combination therapy was non-significantly lower than that of monotherapy or DFO/deferasirox combination therapy (p=0.25).